Pegrizeprument Market Assessment And Sales Forecast To 2034: Orphan Designations Expand Market Potential
Dublin, Sept. 10, 2026 (GLOBE NEWSWIRE) -- The "Pegrizeprument Sales Forecast, and Market Size Analysis - 2034" has been added to ResearchAndMarkets.com's offering.
The report provides a comprehensive assessment of pegrizeprument in transplant rejection across the seven major markets (7MM): the United States, Germany, France, Italy, Spain, the United Kingdom, and Japan. The analysis covers the 2020-2034 study period and evaluates the therapy's clinical development, regulatory progress, commercial potential, competitive positioning, pricing outlook, and forecast sales.
Key Factors Driving Pegrizeprument Market Growth
- Significant unmet need in solid organ transplantation: More than 150,000 solid organ transplants are performed worldwide each year. Recipients typically require lifelong immunosuppressive therapy to prevent graft rejection. Calcineurin inhibitor-based regimens, including tacrolimus, are effective but can be associated with nephrotoxicity, metabolic complications, infections, malignancies, and chronic graft dysfunction. Pegrizeprument is being developed as a targeted maintenance immunosuppressive therapy with the potential to reduce treatment-related toxicities. Differentiated CD28-selective mechanism: Pegrizeprument selectively inhibits CD28-mediated T-cell co-stimulation while preserving CTLA-4 inhibitory signaling. This profile may support immune suppression while maintaining physiological immune regulation. Preclinical non-human primate findings presented at the 2025 World Transplant Congress demonstrated prolonged rejection-free survival and reduced donor-specific antibody formation compared with conventional tacrolimus-based regimens. Development across multiple transplant indications: Although kidney transplantation remains the lead clinical focus, development also includes liver and heart transplantation. U.S. Food and Drug Administration Orphan Drug Designations for the prevention of rejection following liver and heart transplantation broaden the candidate's potential addressable market. Regulatory and commercial incentives: Orphan Drug Designation may provide regulatory support, development incentives, fee reductions, and potential market exclusivity following approval, subject to applicable statutory requirements. Established commercialization capabilities: Veloxis Pharmaceuticals licensed worldwide rights to develop, manufacture, and commercialize pegrizeprument for transplant indications from OSE Immunotherapeutics in 2021. Veloxis' transplant portfolio, clinical expertise, and relationships with transplant centers may support commercialization if the candidate receives regulatory approval.
Recent Pegrizeprument Development
In April 2026, the FDA granted Orphan Drug Designation to pegrizeprument for the prevention of heart allograft rejection in heart transplant recipients. The designation represents an important regulatory milestone and complements the candidate's development in kidney and liver transplantation.
Pegrizeprument Drug Summary
Pegrizeprument, also known by the development codes VEL-101 and FR104, is an investigational pegylated, humanized, monovalent anti-CD28 monoclonal antibody fragment being developed by Veloxis Pharmaceuticals under license from OSE Immunotherapeutics. It is intended for the prevention of acute organ rejection in solid organ transplant recipients.
The candidate binds selectively to the CD28 co-stimulatory receptor on T cells, inhibiting CD28-mediated effector T-cell activation while preserving the CTLA-4 inhibitory pathway. Pegrizeprument is administered by intravenous infusion and is being evaluated as maintenance immunosuppressive therapy in kidney, liver, and heart transplantation. Its targeted mechanism may offer clinical differentiation from conventional calcineurin inhibitors, although efficacy and safety remain subject to confirmation in clinical studies and regulatory review.
Scope of the Pegrizeprument Market Report
- Pegrizeprument mechanism of action, product profile, dosage, administration, and clinical development activities. Regulatory milestones, Orphan Drug Designations, expected development timelines, and potential launch scenarios. Historical, current, and forecast pegrizeprument sales through 2034 across the 7MM. Market size estimates for transplant rejection and relevant solid organ transplant indications. Pricing assumptions, reimbursement considerations, regional cost variations, and peak sales forecasts. Patent analysis, potential generic entry, exclusivity considerations, and anticipated pricing impact. Clinical trial information, including interventions, conditions, trial status, and expected completion dates. Competitive intelligence covering marketed immunosuppressive therapies and late-stage pipeline candidates. SWOT analysis, analyst perspectives, market barriers, growth drivers, and strategic opportunities. Licensing agreements, commercial partnerships, mergers and acquisitions, and other industry activity.
Pegrizeprument Market and Clinical Assessment
The report evaluates the commercial outlook for pegrizeprument in the United States, the EU4, the United Kingdom, and Japan. Forecasts consider the eligible transplant population, clinical adoption, competitive therapies, regulatory timing, pricing, reimbursement, route of administration, treatment duration, and potential uptake across kidney, liver, and heart transplantation.
The clinical assessment examines available pegrizeprument trial data, development status, study design, endpoints, timelines, and anticipated milestones. It also reviews the candidate's potential efficacy and safety differentiation relative to established immunosuppressive regimens and emerging transplant rejection therapies.
Competitive Landscape and Revenue Potential
The pegrizeprument competitive landscape includes established immunosuppressants, marketed transplant products, and emerging therapies in clinical development. The analysis assesses the number of competing candidates, anticipated launch dates, therapeutic positioning, strengths and limitations, and factors that could affect market penetration.
Pegrizeprument's revenue potential will depend on successful clinical development, regulatory approval, demonstrated safety and efficacy, physician acceptance, transplant-center adoption, reimbursement, and differentiation from existing standards of care. Expansion into multiple solid organ transplant indications could increase its long-term commercial opportunity, while competition from late-stage therapies may influence pricing and market share.
Key Questions Addressed
- What are pegrizeprument's mechanism of action, route of administration, and therapeutic class? What is the candidate's clinical trial status across kidney, liver, and heart transplantation? Which regulatory designations have been granted, and how could they affect development and commercialization? What are the projected pegrizeprument market size and sales through 2034 in the 7MM? Which assumptions support the pegrizeprument sales forecast and peak revenue estimates? How could pricing, reimbursement, treatment duration, and regional cost differences affect adoption? Which marketed products and emerging transplant rejection therapies could compete with pegrizeprument? What licensing agreements, partnerships, and strategic activities are associated with the program? What are pegrizeprument's principal clinical, regulatory, and commercial strengths and risks?
The report supports pharmaceutical companies, investors, healthcare organizations, and other stakeholders evaluating the pegrizeprument market opportunity, transplant rejection treatment landscape, competitive environment, and potential sales performance through 2034.
Key Topics Covered
1. Report Introduction
2. Pegrizeprument Overview in potential indication like Transplant rejection
2.1. Product Detail
2.2. Pegrizeprument Clinical Development
2.2.1. Pegrizeprument Clinical studies
2.2.2. Pegrizeprument Clinical trials information
2.2.3. Safety and efficacy
2.3. Other Developmental Activities
2.4. Product Profile
3. Pegrizeprument Competitive Landscape (Marketed Therapies)
4. Competitive Landscape (Late-stage Emerging Pegrizeprument Therapies)
5. Pegrizeprument Market Assessment
5.1. Pegrizeprument Market Outlook in potential indications
5.2. 7MM Analysis
5.2.1. Pegrizeprument Market Size in the 7MM for potential indications
5.3. Country-wise Market Analysis
5.3.1. Pegrizeprument Market Size in the United States for potential indications
5.3.2. Pegrizeprument Market Size in Germany for potential indications
5.3.3. Pegrizeprument Market Size in France for potential indications
5.3.4. Pegrizeprument Market Size in Italy for potential indications
5.3.5. Pegrizeprument Market Size in Spain for potential indications
5.3.6. Pegrizeprument Market Size in the United Kingdom for potential indications
5.3.7. Pegrizeprument Market Size in Japan for potential indications
6. Pegrizeprument SWOT Analysis
7. Analysts' Views
8. Appendix
8.1. Bibliography
8.2. Report Methodology
List of Tables
Table 1: Pegrizeprument, Clinical Trial Description, 2023
Table 2: Pegrizeprument, General Description
Table 3: Competitive Landscape (Marketed Therapies)
Table 4: Competitive Landscape (Emerging Therapies)
Table 5: Pegrizeprument's pricing and cost Assumptions
Table 6: Pegrizeprument's Sales Analysis in the 7MM, in USD million (2020-2034)
Table 7: Pegrizeprument Market Size in the US, in USD million (2020-2034)
Table 8: Pegrizeprument Market Size in Germany, in USD million (2020-2034)
Table 9: Pegrizeprument Market Size in France, in USD million (2020-2034)
Table 10: Pegrizeprument Market Size in Italy, in USD million (2020-2034)
Table 11: Pegrizeprument Market Size in Spain, in USD million (2020-2034)
Table 12: Pegrizeprument Market Size in the UK, in USD million (2020-2034)
Table 13: Pegrizeprument Market Size in Japan, in USD million (2020-2034)
List of Figures
Figure 1: Pegrizeprument's Sales Analysis in the 7MM, USD million (2020-2034)
Figure 2: Pegrizeprument Market Size in the United States, USD million (2020-2034)
Figure 3: Pegrizeprument Market Size in Germany, USD million (2020-2034)
Figure 4: Pegrizeprument Market Size in France, USD million (2020-2034)
Figure 5: Pegrizeprument Market Size in Italy, USD million (2020-2034)
Figure 6: Pegrizeprument Market Size in Spain, USD million (2020-2034)
Figure 7: Pegrizeprument Market Size in the United Kingdom, USD million (2020-2034)
Figure 8: Pegrizeprument Market Size in Japan, USD million (2020-2034)
For more information about this report visit
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.
Comments
No comment